Digital healthcare is becoming a bigger part of the medical technology industry. Compumedics’ earnings show that this shift is already happening, reflecting broader market growth across healthcare technology. The company reported record FY26 revenue despite supply chain delays. It also saw strong growth in its software business. Together, these results point to a stronger foundation for future growth.
Compumedics reported shipped and invoiced revenue of about A$60.3 million for FY26. That is 18% higher than last year. The result was slightly below the company’s earlier forecast of A$62 million to A$65 million.
Compumedics said the lower figure was not caused by weak demand. Instead, some MEG equipment shipments were delayed. The delays happened because helium supplies were disrupted during the conflict in the Middle East.
Customer demand remained strong throughout the year. The Compumedics FY26 revenue update showed A$62.7 million in sales orders. These orders covered sleep diagnostics, neurology, MEG systems, and connected healthcare products. The strong order book gives Compumedics a good starting point for FY27. As delayed shipments are completed, more of those orders can turn into revenue. The company’s software business delivered the strongest growth. Revenue from Somfit and Nexus 360 increased 70% from last year to A$10.2 million, making this an important software news development for the healthcare technology sector.
This growth has been steady. SaaS revenue rose from A$4.3 million in FY24 to A$6 million in FY25. It then reached A$10.2 million in FY26. The growth has been steady over the past three years. It shows that more hospitals and clinics are using Compumedics’ digital healthcare tools.
Think of it this way. A medical device earns money when it is sold. Software subscriptions earn money month after month. This gives Compumedics a steadier income and reduces its dependence on large equipment sales.
- Hospitals and clinics can manage patient records more easily with connected software.
- Doctors can review test results faster, helping them make quicker decisions.
- Patients could receive faster follow-up care because health data is easier to access and share.
- The planned US launch of Somfit D could open a much larger market for the company’s sleep monitoring technology.
- A strong order book gives Compumedics confidence for FY27, even after recent shipment delays.
Compumedics also expects higher operating profits (EBITDA) for FY26. Compumedics expects higher operating profits (EBITDA) in FY26. The company said stronger revenue will play a key role. Careful spending and higher software income are also expected to support profit growth. Its MEG business also recovered during the year. The segment generated A$9.7 million in revenue after recording no revenue in FY25.
Compumedics also announced a board change. Non-executive director Christopher Barys stepped down on June 30. CEO Dr. David Burton thanked him for supporting the company’s US growth strategy and investor engagement during his time on the board. Compumedics expects another year of double-digit revenue growth in FY27. It also expects operating profits to grow faster than revenue.
The latest Compumedics earnings show more than a record revenue year. They show a business that is adding digital healthcare services to its traditional medical device business. The next step is to turn its strong order book and expanding software business into higher earnings during FY27.
Author’s Note:
Compumedics’ latest earnings show that the story goes beyond record revenue. Subscription software is becoming a bigger part of Compumedics’ business. This gives the company a steadier source of income. From an industry analysis perspective, this shift could make the business more resilient over time. The next key test will be whether it can turn its strong order pipeline and planned US expansion into sustained growth in FY27.
Leave a comment